Natixis Advisors L.P. Cuts Stock Holdings in Encompass Health Co. (NYSE:EHC)

Natixis Advisors L.P. lessened its stake in Encompass Health Co. (NYSE:EHC - Free Report) by 55.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 78,594 shares of the company's stock after selling 96,069 shares during the quarter. Natixis Advisors L.P. owned approximately 0.08% of Encompass Health worth $5,243,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Invesco Ltd. raised its stake in Encompass Health by 22.3% during the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company's stock valued at $266,914,000 after purchasing an additional 724,544 shares in the last quarter. William Blair Investment Management LLC raised its stake in Encompass Health by 6.4% during the third quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company's stock valued at $381,226,000 after purchasing an additional 342,512 shares in the last quarter. California Public Employees Retirement System raised its stake in Encompass Health by 160.5% during the fourth quarter. California Public Employees Retirement System now owns 515,717 shares of the company's stock valued at $34,409,000 after purchasing an additional 317,730 shares in the last quarter. Lisanti Capital Growth LLC purchased a new stake in Encompass Health during the third quarter valued at $10,410,000. Finally, FMR LLC raised its stake in Encompass Health by 11.6% during the third quarter. FMR LLC now owns 1,374,755 shares of the company's stock valued at $92,329,000 after purchasing an additional 142,633 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Barclays boosted their price objective on shares of Encompass Health from $101.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Wednesday, February 7th. Truist Financial boosted their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the company a "buy" rating in a research report on Friday, February 9th. Finally, Stephens reiterated an "overweight" rating and set a $85.00 price objective on shares of Encompass Health in a research report on Tuesday, January 16th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $90.29.

Insiders Place Their Bets

In other Encompass Health news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares in the company, valued at approximately $46,139,740.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Greg D. Carmichael purchased 2,000 shares of the firm's stock in a transaction on Friday, May 3rd. The stock was acquired at an average cost of $83.73 per share, with a total value of $167,460.00. Following the completion of the transaction, the director now owns 17,050 shares in the company, valued at approximately $1,427,596.50. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the sale, the chief executive officer now directly owns 554,098 shares of the company's stock, valued at $46,139,740.46. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Encompass Health Trading Up 0.2 %

Shares of NYSE EHC traded up $0.16 during mid-day trading on Friday, reaching $86.53. The company had a trading volume of 719,298 shares, compared to its average volume of 709,185. The business's 50-day moving average is $80.24 and its 200-day moving average is $72.32. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 1.35 and a beta of 0.92. Encompass Health Co. has a 52 week low of $57.55 and a 52 week high of $86.72.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The firm had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.27 billion. During the same period in the prior year, the business posted $0.88 earnings per share. The business's revenue for the quarter was up 13.4% on a year-over-year basis. Equities analysts expect that Encompass Health Co. will post 4.09 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, June 28th. Encompass Health's payout ratio is 16.22%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.